Почетна › Akutna mijeloidna leukemija › Пенсилванија
Kliničke studije za Akutna mijeloidna leukemija u državi Пенсилванија
44 studija za Akutna mijeloidna leukemija traži učesnike na lokacijama u državi Пенсилванија.
Gradovi u državi Пенсилванија
- Philadelphia33 студија
- Pittsburgh18 студија
- Harrisburg8 студија
- Allentown8 студија
- Scranton7 студија
- Reading5 студија
Zvanični tekst studije (na engleskom)
Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- и још 4
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT06317649Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 12. 11. 2026. · NCT07007312Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- и још 6
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 9. 11. 2026. · NCT05554406Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
- US-Pittsburgh PA-PITT, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07223814Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
- Thomas Jefferson University Hospital, Philadelphia
- Geisinger Wyoming Valley/Henry Cancer Center, Wilkes-Barre
Тражи се учесникФаза 2
Узраст 60 и старији · Оба пола · Ажурирано 6. 11. 2026. · NCT07437950Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Lehigh Valley Hospital - Muhlenberg, Bethlehem
- Geisinger Medical Center, Danville
- и још 7
Тражи се учесникОпсервациона студијаЗдраве особе су добродошле
Узраст од 40 до 75 · Оба пола · Ажурирано 4. 11. 2026. · NCT05334069A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
- Thomas Jefferson University, Philadelphia
- Fox Chase Cancer Center, Philadelphia
- University of Pittsburgh Medical Center, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 3. 11. 2026. · NCT06852222MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- и још 6
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 2. 11. 2026. · NCT05564390Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution
- Children's Hospital of Philadelphia, Philadelphia
Тражи се учесникОпсервациона студија
Узраст од 0 до 38 · Оба пола · Ажурирано 29. 10. 2026. · NCT06131801Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Milton S Hershey Medical Center, Hershey
- и још 4
Тражи се учесникФаза 2
Узраст од 18 до 59 · Оба пола · Ажурирано 28. 10. 2026. · NCT05554393Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)
- Geisinger Medical Center, Danville
- Thomas Jefferson University Hospital, Philadelphia
- UPMC Hillman Cancer Center, Pittsburgh
- и још 1
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 27. 10. 2026. · NCT06672146A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 23. 10. 2026. · NCT07012044Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
Тражи се учесникФаза 1
Узраст од 1 до 30 · Оба пола · Ажурирано 22. 10. 2026. · NCT06177067Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
- University of Pittsburgh Cancer Institute (UPCI), Pittsburgh
Тражи се учесникФаза 2
Узраст од 1 до 60 · Оба пола · Ажурирано 20. 10. 2026. · NCT03970096Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
- UPENN Perelman Center for Advanced Medicine, Philadelphia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 16. 10. 2026. · NCT06846606A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1/2
30 Days · Оба пола · Ажурирано 9. 10. 2026. · NCT04065399A Longitudinal Multi-Center Molecular Biomarker Discovery Registry for Patients With Hematologic Malignancies
- Cancer Care Associates of York, York
Тражи се учесникОпсервациона студија
Узраст 0 и старији · Оба пола · Ажурирано 9. 10. 2026. · NCT07154823Assessment of Geriatric Evaluations Impact on New AML Guidance
- Abramson Cancer Center at University of Pennsylvania, Philadelphia
Тражи се учесникОпсервациона студија
Узраст 50 и старији · Оба пола · Ажурирано 2. 10. 2026. · NCT05909501A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- и још 3
Тражи се учесникФаза 3
6 Months – 21 Years · Оба пола · Ажурирано 17. 9. 2026. · NCT04293562Evaluation of Two Dose Levels of Quizartinib as Maintenance in FLT3-ITD (+) Acute Myeloid Leukemia Patients in Complete Remission
- Spoknwrd Clinical Trials Inc., Easton
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 16. 9. 2026. · NCT06824168A Study of BGB-11417 in Participants With Myeloid Malignancies
- Upmc Hillman Cancer Center(Univ of Pittsburgh), Pittsburgh
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 14. 9. 2026. · NCT04771130Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia
- Geisinger Medical Center, Danville
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh of UPMC, Pittsburgh
Тражи се учесникФаза 3
Узраст од 1 до 25 · Оба пола · Ажурирано 4. 9. 2026. · NCT07022678Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML
- US-Pittsburgh PA-PITT, Pittsburgh
Тражи се учесникФаза 3
Узраст 18 и старији · Оба пола · Ажурирано 2. 9. 2026. · NCT06652438The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study
- Lehigh Valley Hospital-Cedar Crest, Allentown
- Geisinger Medical Center, Danville
- Penn State Children's Hospital, Hershey
- и још 3
Тражи се учесникФаза 1/2
До 22 година · Оба пола · Ажурирано 25. 8. 2026. · NCT04726241Thiotepa-based Conditioning Regimen With De-escalated Post-graft Cyclophosphamide for Allogeneic Stem Cell Transplantation in Hematologic Malignancies
- UMPC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 18. 8. 2026. · NCT07565220Interferon-γ (IFN-γ) With Donor Leukocyte Infusion to Treat Relapsed Acute Myeloid Leukemia and Myelodysplastic Syndromes Post Allogeneic Hematopoietic Stem Cell Transplantation
- UPMC Hillman Cancer Center, Pittsburgh
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 11. 8. 2026. · NCT06529731L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 2/3
Узраст од 18 до 80 · Оба пола · Ажурирано 5. 8. 2026. · NCT06788756Tagraxofusp and Azacitidine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents
- Penn Medicine Abramson Cancer Center, Philadelphia
Тражи се учесникФаза 2
Узраст 18 и старији · Оба пола · Ажурирано 10. 7. 2026. · NCT05442216CD33KO-HSPC Infusion Followed by CART-33 Infusion(s) for Refractory/Relapsed AML
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 9. 7. 2026. · NCT05945849CD45RA Depleted Peripheral Stem Cell Addback for Viral or Fungal Infections Post TCRαβ/CD19 Depleted HSCT
- Children's Hospital of Philadelphia, Philadelphia
Тражи се учесник
До 25 година · Оба пола · Ажурирано 8. 7. 2026. · NCT03810196CART123 Cells With or Without Ruxolitinib in Relapsed/Refractory Acute Myeloid Leukemia
- Children's Hospital of Philadelphia, Philadelphia
Тражи се учесникФаза 1
Узраст од 0 до 29 · Оба пола · Ажурирано 7. 7. 2026. · NCT07464951A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)
- Penn State Milton S. Hershey Cancer Center, Hershey
- Children's Hospital of Philadelphia, Philadelphia
- Children's Hospital of Pittsburgh, Pittsburgh
- и још 3
Тражи се учесникОпсервациона студија
Сви узрасти · Оба пола · Ажурирано 6. 7. 2026. · NCT01351545Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies
- Penn Medicine - Abramson Cancer Center Perelman, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 24. 6. 2026. · NCT04068597SNDX-5613 and Gilteritinib for the Treatment of Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia and Concurrent MLL-Rearrangement or NPM1 Mutation
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 14. 5. 2026. · NCT06222580Study of Talazoparib in Combination With Chemotherapy in Relapsed Pediatric AML to Determine Safety and Efficacy
- Pennsylvania State University Hershey Medical Center, Hershey
Тражи се учесникФаза 1
До 21 година · Оба пола · Ажурирано 22. 4. 2026. · NCT05101551Massage Impact on Sleep in Pediatric Oncology
- Children's Hospital of Philadelphia, Philadelphia
Тражи се учесник
Узраст од 12 до 21 · Оба пола · Ажурирано 15. 4. 2026. · NCT06892158A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)
- Sidney Kimmel Comprehensive Cancer Center, Philadelphia
- Allegheny Health Network, Pittsburgh
Тражи се учесникФаза 1/2
Узраст 12 и старији · Оба пола · Ажурирано 24. 3. 2026. · NCT04988555Phase IB/II of CPX-351 for Relapse Prevention in AML
- University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1/2
Узраст 18 и старији · Оба пола · Ажурирано 23. 3. 2026. · NCT04990102A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid Leukemias
- Thomas Jefferson University Hospital, Philadelphia
Тражи се учесникФаза 1
Узраст 12 и старији · Оба пола · Ажурирано 16. 3. 2026. · NCT06994676A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- Hospital of the University of Pennsylvania, Philadelphia
Тражи се учесникФаза 1
Узраст 18 и старији · Оба пола · Ажурирано 13. 3. 2026. · NCT05735184Sa sajta ClinicalTrials.gov, podaci preuzeti 15. 11. 2026.. Svaka studija ima svoje kriterijume za uključivanje; tim studije odlučuje ko može da učestvuje.